Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 3, 2003, Pages 396-402

  Lassen, U ^a,c   Daugaard, G ^a   Eigtved, A ^b   Hojgaard L ^b   Damgaard, K ^b   Rorth M ^a  

^a FINSEN LABORATORY   (Denmark)

^b Rigshospitalet   (Denmark)

^c HILLERØD HOSPITAL   (Denmark)

Author keywords

Fluorodeoxyglucose; Germ cell tumours; PET; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ADULT; APPARATUS; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DENMARK; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DRUG UPTAKE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; MALE; METASTASIS; NON INVASIVE MEASUREMENT; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; POSITRON EMISSION TOMOGRAPHY; RETROPERITONEAL CANCER; SENSITIVITY AND SPECIFICITY;

EID: 0037870283     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-1075-z     Document Type: Article

References (51)

1. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1996; 337:242-253.
2. Peckham MJ, Barrett A, Husband JE, et al. Orchiectomy alone in testicular stage I non-seminomatous germ-cell tumours. Lancet 1982; 2:678-680.
3. Daugaard G, Hansen HH, Rorth M. Treatment of malignant germ cell tumors. Ann Oncol 1990; 1:195-202.
4. Gels ME, Hoekstra HJ, Sleijfer DT, et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 1995; 13:1188-1194.
5. Sogani PC, Perrotti M, Herr HW, et al. Clinical stage I testis cancer: long term outcome of patients on surveillance. J Urol 1998; 159:855-858.
6. Sturgeon JF, Jewett MA, Alison RE, et al. Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. J Clin Oncol 1992; 10:564-568.
7. Donohue JP, Thornhill JA, Foster RS, et al. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965-1989. Br J Urol 1993; 71:326-335.
8. Klepp O, Olsson AM, Henrikson H, et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study: Swedish-Norweigian Testicular Cancer Group. J Clin Oncol 1990; 8:509-518.
9. Sweeney CJ, Hermans BP, Heilman DK, et al. Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant testis cancer. J Clin Oncol 2000; 18:358-362.
10. Pont J, Albrecht W, Postner G, et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996; 14:441-448.
11. Cullen MH, Stenning SP, Parkinson MC, et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 1996; 14:1106-1113.
12. Bohlen D, Borner M, Sonntag RW, et al. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 1999; 161:1148-1152.
13. Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer Detection with whole-body PET using 2-(18F)fluoro-2-deoxy-d-glucose. J Comput Assist Tomogr 1993; 17:582-589.
14. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991; 32:623-648.
15. Laubenbacher C, Saumweber D, Wagner-Manslau C, et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 1995; 36:1747-1757.
16. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron emission tomography [comment]. N Engl J Med 2000; 343:254-261.
17. Wahl RL, Cody RL, Hutchins GD, et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-d-glucose. Radiology 1991; 179:765-770.
18. Rodriguez MA, Rehn S, Ahlström H, et al. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995; 36:1790-1796.
19. Beets G, Penninckx F, Schiepers C, et al. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Cancer 1994; 81:1666-1670.
20. Rinne D, Baum RP, Hor G, et al. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998; 82:1664-1671.
21. Warburg O: On the origin of cancer. Science 1956; 123:309-311.
22. Som P, Atkins HL, Bardoypadhyay D. A fluorinated glucose analogue 2-fluoro-2-deoxy-d-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21:670-675.
23. Phelps ME, Hoffman EJ, Huang SC. ECAT: a new computerised tomographic imaging system for positron emitting radiopharmaceuticals. J Nucl Med 1978; 19:635-647.
24. Wahl RL, Greenough RL, Clarke MF, et al. Initial evaluation of FDG/PET imaging of metastatic testicular neoplasms [abstract]. J Nucl Med 1993; 34:6.
25. Stephens AW, Gonin R, Hutchins GD, et al. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 1996; 14:1637-1641.
26. Nuutinen JM, Leskinen S, Elomaa I, et al. Detection of residual tumours in postchemotherapy testicular cancer by FDGPET. Eur J Cancer 1997; 33:1234-1241.
27. Hain SF, O'Doherty MJ, Timothy AR, et al. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 2000; 83:863-869.
28. Albers P, Bender H, Yilmaz H, et al. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology 1999; 53:808-811.
29. Hain SF, O'Doherty MJ, Timothy AR, et al. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 2000; 27:590-594.
30. De Santis M, Bokemeyer C, Becherer A, et al. Predictive impact of 2-18fluoro-2-deoxy-d-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001; 19:3740-3744.
31. Sugawara Y, Zasadny KR, Grossman HB, et al. Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. Radiology 1999; 211:249-256.
32. Cremerius U, Effert PJ, Adam G, et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med 1998; 39:815-822.
33. Wilson CB, Young HE, Ott RJ, et al. Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med 1995; 22:508-513.
34. Reinhardt MJ, Muller-Mattheis VG, Gerharz CD, et al. FDGPET evaluation of retroperitoneal metastases of testicular cancer before and after chemotherapy. J Nucl Med 1997; 38:99-101.
35. Bokemayer C, Kollmannsberger C, Oechsle K, et al. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [18F]FDG PET. Br J Cancer 2002; 86:506-511.
36. Kollmannsberger C, Oechsle K, Dohmen BM, et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer 2002; 94:2353-2362.
37. Engel H, Steinert H, Buck A, et al. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 1996; 37:441-446.
38. DeGrado TR, Turkington TG, Williams JJ, et al. Performance characteristics of a whole-body PET scanner. J Nucl Med 1994; 35:1398-1406.
39. Cremerius U, Fabry U, Neuerburg J, et al. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998; 19:1055-1063.
40. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose: variation with body weight and a method for correction. Radiology 1993; 189:847-850.
41. Lindholm P, Minn H, Leskinen-Kallio S, et al. Influence of the blood glucose concentration on FDG uptake in cancer - a PET study. J Nucl Med 1993; 34:1-6.
42. Langen K-J, Braun U, Kops ER, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 1993; 34:355-359.
43. Bleckmann C, Dose J, Bohuslavizki KH, et al. Effect of attenuation correction on lesion detectability in FDG PET of breast cancer. J Nucl Med 1999; 40:2021-2024.
44. Farquhar TH, Llacer J, Hoh CK, et al. ROC and localization ROC analyses of lesion detection in whole-body FDG PET: effects of acquisition mode, attenuation correction and reconstruction algorithm. J Nucl Med 1999; 40:2043-2052.
45. Fischman AJ, Alpert NM. FDG-PET in oncology: there's more to it than looking at pictures [editorial]. J Nucl Med 1993; 34:6-11.
46. Studer UE, Burkhard FC, Sonntag RW. Risk adapted management with adjuvant chemotherapy in patients with high risk clinical stage I nonseminomatous germ cell tumer. J Urol 2000; 163:1785-1787.
47. Moul JW, McCarthy WF, Fernandez EB, et al. Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. Cancer Res 1994; 54:362-364.
48. Albers P, deRiese W, Walker EB, et al. Predictive parameters in biologic assessment of low-stage retroperitoneal lymphnode dissection. World J Urol 1994; 12:120-124.
49. Hilton S, Herr HW, Teitcher JB, et al. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. Am J Roentgenol 1997; 169:521-525.
50. Gels ME, Marrink J, Visser P, et al. Importance of a new tumor marker TRA-1-60 in the follow-up of patients with clinical stage I nonseminomatous testicular germ cell tumors. Ann Surg Oncol 1997; 4:321-327.
51. Fernandez EB, Moul JW, Foley JP, et al. Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. Urology 1994; 44:548-552.